Price
No data yet.
Social Signal Score
Analyst Ratings
7 analystsRevenue
$299.0KAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Philip A. Serlin
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 22
- Beta
- 0.69
- Country
- IL
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -17.31
Financials
Revenue
$299.0K-93.8%Net Income
$-3.08MEBITDA
$-3.56MFree Cash Flow
$-3.26MEPS (diluted)
$-0.70Shares Outstanding (diluted)
4.44M+4621.5%Operating Expenses
$3.79MCash & Debt
$13.08MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.19M | $-1.18M | $-0.29 |
| 2024 | $28.94M | $-9.22M | $-4.62 |
| 2023 | $4.80M | $-60.61M | $-37.74 |
| 2022 | $0.00 | $-24.95M | $-19.32 |
| 2021 | $0.00 | $-27.05M | $-24.48 |
| 2020 | $0.00 | $-30.02M | $-72.00 |
| 2019 | $0.00 | $-25.45M | $-108.00 |
| 2018 | $0.00 | $-22.96M | $-126.00 |
| 2017 | $0.00 | $-24.35M | $-162.00 |
| 2016 | $0.00 | $-15.84M | $-168.00 |
| 2015 | $0.00 | $-14.40M | $-168.00 |
| 2014 | $0.00 | $-10.17M | $-186.00 |
| 2013 | $0.00 | $-17.64M | $-468.00 |
| 2012 | $0.00 | $-20.42M | $-726.00 |
Valuation
BLRXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (5)
- Newsprnewswire.com·29d ago·Neutral
BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026) TEL AVIV, Israel and OSLO, Norway, Sept. 10, 2026 /PRNewswire/ -- BioLineRx Ltd.
View source ↗ - Newsseekingalpha.com·39d ago·Positive
BioLineRx Ltd. (BLRX) Q2 2026 Earnings Call Transcript BioLineRx Ltd. (BLRX) Q2 2026 Earnings Call Transcript
View source ↗ - Newsprnewswire.com·39d ago·Positive
…cer xenograft model - - Management to host conference call today, August 31, at 8:30 am EDT - TEL AVIV, Israel, Aug. 31, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended June 30, 2026, and provided a corporate update.
View source ↗ - Newsprnewswire.com·42d ago·Negative
BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement TEL AVIV, Israel, Aug. 28, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into a definitive agreement for the purchase of an aggregate of 1,348,921 of the Company's American Depositary Shares (ADSs) (or ADS equival…
View source ↗ - Newsprnewswire.com·45d ago·Neutral
BioLineRx to Report Second Quarter 2026 Results on August 31, 2026 Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel, Aug. 25, 2026 /PRNewswire/ -- BioLineRx Ltd.
View source ↗
Earnings
Mon, Nov 23(in 6 weeks)
Consensus estimate $-0.39 per share
Typical surprise +32.0% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 31$-0.77 vs $-0.15miss
- Wed, May 27$-0.58 vs $-1.04beat
- Mon, Mar 23$-0.34 vs $-0.50beat
- Mon, Nov 24$-0.22 vs $-0.41beat
- Thu, Aug 14$-1.00 vs $-0.35miss
- Tue, May 27$1.39 vs $-0.84beat
Estimates and results for BLRX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BLRX officers and directors.
No open-market trades in the recent filings. All 68 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
68 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in BLRX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.